PRODUCT INFORMATION



Afuresertib (hydrochloride)

Item No. 17988

CAS Registry No.: Formal Name:	1047645-82-8 N-[(1S)-2-amino-1-[(3-fluorophenyl)methyl] ethyl]-5-chloro-4-(4-chloro-1-methyl-1H- pyrazol-5-yl)-2-thiophenecarboxamide, monohydrochloride
Synonym:	GSK2110183B
MF:	C ₁₈ H ₁₇ Cl ₂ FN ₄ OS • HCl
FW:	463.8
Purity:	≥98% •HCi
UV/Vis.:	λ_{max} : 230, 262 nm $Cl = \sqrt{N}$
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Afuresertib (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the afuresertib (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Afuresertib (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of afuresertib (hydrochloride) in ethanol and DMF is approximately 50 mg/ml and approximately 30 mg/ml in DMSO.

Afuresertib (hydrochloride) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, afuresertib (hydrochloride) should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Afuresertib (hydrochloride) has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Afuresertib is a pan-Akt inhibitor (IC₅₀s = 0.08, 2, and 2.6 nM for Akt1, -2, and -3, respectively).¹ It is selective for Akt over a panel of 13 kinases ($IC_{50}s = >100 \text{ nM}$) but does inhibit PKA, PKG1 α , and PKG1 β ($IC_{50}s = 1.3$, 0.9, and 4 nM, respectively). Afuresertib (10, 30, and 100 mg/kg) inhibits tumor growth in an SKOV3 mouse xenograft model.

Reference

1. Dumble, M., Crouthamel, M.C., Zhang, S.Y., et al. Discovery of novel AKT inhibitors with enhanced antitumor effects in combination with the MEK inhibitor. PLoS One 9(6), e100880 (2014).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/02/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM